|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PRDM9 |
 Gene summary |
| Basic gene Info. | Gene symbol | PRDM9 |
| Gene name | PR domain containing 9 | |
| Synonyms | MEISETZ|MSBP3|PFM6|PRMD9|ZNF899 | |
| Cytomap | UCSC genome browser: 5p14 | |
| Type of gene | protein-coding | |
| RefGenes | NM_020227.2, | |
| Description | PR domain zinc finger protein 9histone-lysine N-methyltransferase PRDM9minisatellite binding protein 3 (115kD)minisatellite binding protein 3, 115kDa | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 609760 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000164256 | ||
| HPRD : 17905 | ||
| Vega : OTTHUMG00000161918 | ||
| Protein | UniProt: Q9NQV7 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PRDM9 | |
| BioGPS: 56979 | ||
| Pathway | NCI Pathway Interaction Database: PRDM9 | |
| KEGG: PRDM9 | ||
| REACTOME: PRDM9 | ||
| Pathway Commons: PRDM9 | ||
| Context | iHOP: PRDM9 | |
| ligand binding site mutation search in PubMed: PRDM9 | ||
| UCL Cancer Institute: PRDM9 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006311 | meiotic gene conversion | 21750151 |
| Top |
| Ligand binding site mutations for PRDM9 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C208 | Q209H | BLCA | 1 | C208 | Q209R | HNSC | 1 | C205 | L203I | HNSC | 1 | C390 | C390R | LUAD | 1 | C390 | H388Y | PRAD | 1 | C208 | N210K | SKCM | 1 | H406 | E408K | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PRDM9 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | C205 | L203I | -1.6376875 | H406 | E408K | -1.0107854 | C208 | Q209H | -0.89683744 | C390 | H388Y | -0.83050094 | C208 | N210K | -0.77831064 | C208 | Q209R | -0.59695157 | C390 | C390R | -0.55774024 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PRDM9 from PDB |
| Top |
| Differential gene expression and gene-gene network for PRDM9 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PRDM9 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PRDM9 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PRDM9 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 4ijd | A | C205 C208 | ZN | ZINC(2+) | 4ijd | B | C205 C208 | ZN | ZINC(2+) | 4ijd | A | C390 H406 | ZN | ZINC(2+) | 4ijd | B | C390 H406 |
| Top |
| Conservation information for LBS of PRDM9 |
| Multiple alignments for Q9NQV7 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |